Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 10, 2019

SELL
$7.38 - $9.72 $5.15 Million - $6.78 Million
-697,989 Reduced 18.37%
3,100,864 $25.2 Million
Q4 2018

Feb 06, 2019

SELL
$6.51 - $9.6 $332,986 - $491,040
-51,150 Reduced 1.33%
3,798,853 $30.7 Million
Q3 2018

Nov 08, 2018

BUY
$5.52 - $7.99 $2.09 Million - $3.02 Million
378,565 Added 10.91%
3,850,003 $29.4 Million
Q2 2018

Aug 02, 2018

SELL
$4.6 - $6.52 $152,522 - $216,183
-33,157 Reduced 0.95%
3,471,438 $19.9 Million
Q1 2018

Apr 20, 2018

BUY
$4.35 - $5.82 $1.84 Million - $2.46 Million
422,360 Added 13.7%
3,504,595 $16.7 Million
Q4 2017

Jan 25, 2018

BUY
$4.16 - $5.33 $24,019 - $30,775
5,774 Added 0.19%
3,082,235 $15.1 Million
Q3 2017

Nov 03, 2017

BUY
$4.1 - $5.97 $12.6 Million - $18.4 Million
3,076,461
3,076,461 $16.1 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.